Castle Biosciences Wins 2026 Genomics Innovation Award for AdvanceAD-Tx Test
Castle Biosciences' AdvanceAD-Tx test, a non-invasive gene expression profile analyzing 487 genes across 12 pathways, won the 2026 MedTech Breakthrough Award for genomics innovation—the fifth such award for the company. In validation, patients matching test-guided JAK inhibitor profiles achieved near-clear skin 5.5 times more often and 3.8 times faster.
1. Award Recognition
Castle Biosciences’ AdvanceAD-Tx test was selected as the winner of the Genomics Innovation Award in the 10th annual MedTech Breakthrough Awards, marking the fifth time the company has been honored for its diagnostic innovations.
2. Test Technology
AdvanceAD-Tx employs a non-invasive lesional skin scraping to measure expression of 487 genes across 12 skin and inflammatory pathways, classifying patients into Janus kinase inhibitor Responder or T-helper 2 molecular profiles.
3. Clinical Validation Results
In a prospective, multi-center validation study, patients with a JAK Inhibitor Responder profile treated in alignment with test results were 5.5 times more likely to reach near-clear skin (EASI-90) and achieved that outcome 3.8 times faster, with enhanced itch relief and fewer flares.